Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasmiditan PK and DDI Study
NCT03252015Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lasmiditan in migraine (5 cohorts), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s). Started Aug 2017; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03252015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03252015.